WELCOME TO The Biotechnology REPORT
Serum Source International, Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CELL AND GENE THERAPY
Neurophth | January 19, 2021
Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy.
AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...
GenScript | November 10, 2020
GenScript USA Inc., the world's leading research reagent provider, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first commercially available test to specifically detect neutralizing antibodies without the use of live virus. Neutralizing antibodies, a subset of antibodies that are specifically able to block the ability of the virus to enter a cel...
PR Newswire | June 08, 2020
For biopharma companies seeking increased development and manufacturing capacity for vaccines and therapies, including new COVID-19-related programs, Thermo Fisher Scientific provided highlights of its new capabilities during the BIO International Convention, June 8-12, now a virtual event at www.bio.org/events/bio-digital."We can now provide an uninterrupted path from development to commercialization for biopharma companies, small to large, in geographies worldwide and across vaccine...
RQ Bio | May 17, 2022
RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio's existing mAbs against SARS-CoV-2. The Company, which is headquartered in London, is dedicated to developing treatments and preventative therapies based on potent broad-spectrum mAbs to provide instant and long-lasting immunity for vulnerable people at risk of severe disease or death from existing, emerging a...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE